Skip directly to Accessibility Notice

How to Purchase

BBH
VanEck Vectors Biotech ETF

  • The biotech sector is attracting a wave of investor interest as companies race to meet soaring global demand for COVID-19 diagnostics and treatment.
  • Demand is expected to outstrip supply for the foreseeable future.
  • Optimism about recent developments by some biotech firms has also helped lift the sector’s performance so far this year.
  • Gilead Sciences and Moderna are two of BBH’s top 10 holdings. Gilead recently indicated that the trial for coronavirus treatment Remdesivir has met its initial goal, and the U.S. Food and Drug Administration (FDA) is fast tracking Moderna’s experimental COVID-19 vaccine through the regulatory review process.

Learn more: Race for the Cure Drives Biotech Stocks

Fund Description

VanEck Vectors® Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.

 
 

  • Fund Ticker

    BBH
  • Exchange

    NASDAQ
  • ETF Structure

    Physical
  • Administrator

    Van Eck Associates
  • Custodian

    State Street Bank and Trust Company
  • Index Ticker

    MVBBHTR
  • Index Rebalancing

    Quarterly

 
as of 07/07/20

  • 30-Day SEC Yield1

    0.35%
  • Total Net Assets

    $509.8M
  • Number of Holdings

    24
  • Options

    Available
  • Gross Expense Ratio2

    0.40%
  • Net Expense Ratio/TER2

    0.35%
  • Distribution Frequency

    Annual